Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Glioblastoma × encorafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Melanoma 9 Neoplasm Metastasis 3 Neoplasms 2 Lung Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Brain Neoplasms 2 Solid Tumors Harboring a BRAF V600 Mutation 1 Skin Neoplasms 1 Skin Diseases 1 Pancreatic Neoplasms 1 Lymphatic Metastasis 1 Hematologic Neoplasms 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1 Astrocytoma 1

Interventions

Temozolomide 104 Bevacizumab 64 Radiotherapy 45 Radiation 21 Erlotinib Hydrochloride 12 pembrolizumab 10 Magnetic Resonance Spectroscopy 10 Lomustine 10 Vorinostat 9 Irinotecan 9 Nivolumab 8 Surgical Procedures, Operative 7 Radiotherapy, Intensity-Modulated 7 Immunoglobulin G 7 Disulfides 7 Sorafenib 6 Radiotherapy, Conformal 6 Radiosurgery 6 Drug Therapy 6 Carmustine 6 antineoplaston AS 2-1 5 antineoplaston A10 5 Granulocyte-Macrophage Colony-Stimulating Factor 5 Everolimus 5 veledimex 4 selinexor 4 sargramostim 4 cediranib 4 Dasatinib 4 Cilengitide 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03973918 2024-10-31

BRAF

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Terminated

5 enrolled 15 charts

Astrocytoma, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡